Eli Lilly Announces $1.8 Billion Investment in Ireland, Creating 150 New Jobs

Eli Lilly to create 150 new jobs amid $1bn Limerick investment

The pharmaceutical company also unveiled the $800m expansion to its Kinsale facility, which manufactures medicines targeting obesity and diabetes. Multinational pharmaceutical firm Eli Lilly and Company has today (12 September), revealed an additional investment to the tune of $1bn, in the expansion of the Limerick-based manufacturing site. The site, which is still under construction, will be used to increase the production of biological active ingredients used in a wide range of treatments for Alzheimer's disease. The recent investment is the next phase of Eli Lilly's expansion plans, which has seen the company put more than $20bn towards building, expanding and acquiring US and European-based manufacturing plants. In Limerick, the expansion will create 150 new jobs for professionals highly skilled in engineering, science, quality assurance and operations, bringing the number of employees up to 450, with the plant expected to open in 2026. Minister for Enterprise, Trade and Employment Peter Burke,TD, welcomed the news, stating, "today marks two fantastic investments from Eli Lilly and Company, both the announcement of a $1bn expansion of Lilly's Limerick site in Raheen and the unveiling of the new $800m facility expansion in Kinsale." "These state-of-the-art facilities will contribute to the treatment of diseases affecting millions of people across the world. They will also create hundreds of new jobs, directly and indirectly, adding to the thousands already employed in Ireland by Lilly." Invent. Impact. Inspire. Think for impact with Liberty IT. Delivering global software solutions Unlocking the potential of biology for patients We impact life and health with science Burke noted the commitment Eli Lilly and Company has made to Ireland for nearly half a century, stating that today's announcement is further proof of the multinational's confidence in Ireland as a global leader within the biopharma sector. IDA Ireland CEO Michael Lohan added "since establishing in Ireland in 1978, Lilly's operations here have been producing key healthcare products that have supported the fight against several of the world's most serious illnesses. I wish to assure Lilly of IDA Ireland's continued partnership and wish them every success with the far-reaching outcomes of the investments unveiled today." "Alzheimer's disease is a devastating diagnosis for both the patient and for their loved ones, along with having a huge burden on society," said Anne E. White, executive vice president and president of Lilly Neuroscience. "The treatments we plan to make here in Limerick offer the potential to be able to slow the progression of early symptomatic Alzheimer's disease and make life better for millions of people around the world." Earlier this year Eli Lilly signed a deal with AI drug discovery company Isomorphic Labs, to collaborate on research, with the goal of accelerating cures for some of the world's most devastating diseases. Don't miss out on the knowledge you need to succeed. Sign up for the Daily Brief, Silicon Republic's digest of need-to-know sci-tech news.

Lilly expands manufacturing footprint in Ireland with $1.8 billion investment By Investing.com

Company ups manufacturing investment in Limerick by $1 billion; unveils new $800 million Kinsale facility New investment will enhance global medicine production, benefiting millions of patients worldwide , /PRNewswire/ -- Eli Lilly and Company (NYSE: NYSE:LLY) today announced a expansion of its Limerick, , manufacturing site to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. The company also unveiled its new facility expansion in Kinsale, , which began making medicines last year to meet demand for Lilly's latest diabetes and obesity treatments. This additional investment is part of the most ambitious manufacturing expansion agenda in the company's history. Since 2020, Lilly has committed more than to build, expand and acquire manufacturing facilities in the and . "These investments will boost the production of some of our medicines, helping millions of people with diabetes, obesity and Alzheimer's disease live the healthiest lives possible," said , executive vice president and president of Lilly Manufacturing Operations. "We won't stop there " these state-of-the-art facilities will also be equipped to support our promising pipeline molecules of the future." Limerick, Once complete, Limerick will join Lilly's global manufacturing network producing the biologic active ingredients for the company's Alzheimer's disease portfolio and other biologic medicines. "Alzheimer's disease is a devastating diagnosis for both the patient and for their loved ones, along with having a huge burden on society," said , executive vice president and president of Lilly Neuroscience. "The treatments we will make here in Limerick offer the potential to be able to slow the progression of the disease and make life better for millions of people around the world." Today's announcement brings Lilly's total Limerick investment to , doubling the investment the company announced in . Advanced technologies such as machine learning, AI and automated robotics and systems at the site will enable right-first-time execution, all in support of the safe and reliable supply of medicines. As a part of this expansion, Lilly will create another 150 jobs for highly skilled workers in Limerick such as engineers, scientists, quality assurance professionals and operations personnel, for a total of 450 employees. Lilly initially announced the Limerick site in 2022 and broke ground in . Production of biologic active ingredients for Lilly medicines is on track to start in 2026. The Limerick investment project is subject to planning approval, and the company will submit a planning application to the Limerick City and County Council in due course. Kinsale, Lilly remains dedicated to addressing major global health issues, and the Kinsale facility is pivotal to maintaining the safe and reliable supply of Lilly's diabetes and obesity medications. The official opening of Lilly's Kinsale manufacturing site expansion marks the completion of the state-of-the-art project to help meet the demand for current and future treatments. The site employs a digital-first process that integrates continuous manufacturing technology to create a new manufacturing platform for creating complex peptides. This facility was recently recognized as the winner of the Innovation category in the prestigious "Facility of the Year" awards program run by the International Society of Pharmaceutical Engineers. skilled workforce, regulatory environment and pro-innovation government policies have contributed to Lilly's nearly fifty-year presence in the country. In parallel with our manufacturing growth, Lilly's Global Business Solutions center in Cork has quadrupled employment levels since 2019, with more than 2,000 employees expected by the end of 2024, over half of whom are working in clinical research and development. Sustainability Lilly has a long-standing commitment to sustainability and respecting the local environment, establishing environmental programs across all sites in to monitor the quality of the ambient air, the flora and fauna and the local marine habitat. Once completed, the Limerick site will operate with 35% lower energy intensity, use 40% less water, and generate 15% less waste than traditional biopharmaceutical manufacturing processes. In Kinsale, Lilly has the single largest privately owned solar farm " 26 acres " in the , which powers a significant portion of the facility. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook (NASDAQ:META), Instagram and LinkedIn. C-LLY This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about planned capital investments in manufacturing sites and reflects Lilly's current beliefs and expectations. There are substantial risks and uncertainties in the manufacturing process, development, and commercialization of pharmaceutical products which could impact the overall commercial success of our products. For further discussion of risks and uncertainties relevant to Lilly's business that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Eli Lilly doubles down on Irish operations with $1.8 bln Investment By Investing.com

Investing.com -- Eli Lilly and Company (NYSE:LLY) on Thursday announced a $1.8 billion investment to expand its manufacturing operations in Ireland. This decision will enhance the production of biologic active ingredients, particularly for treatments targeting Alzheimer's disease and obesity. The investment will be directed toward two major expansion projects in Ireland. The first of these is a $1 billion expansion at Lilly's Limerick site. This development will double the company's initial investment announced in March 2023, bringing the total commitment to a substantial $2 billion. Once complete, the Limerick facility will become a pivotal component in Lilly's global manufacturing network, focusing on producing biologic active ingredients for its recently approved Alzheimer's treatment and other biologic medicines. The expansion will introduce advanced technologies such as machine learning, artificial intelligence, and automated robotics to ensure precise and efficient manufacturing processes. It will also generate 150 new high-skilled jobs, increasing the workforce at Limerick to 450 employees by the time production begins in 2026. The project is currently awaiting planning approval, with a formal application to be submitted to the Limerick City and County Council. Simultaneously, Eli Lilly is investing $800 million to enhance its Kinsale facility, which began operations last year. "Investment in these two locations in Ireland (Limerick & Kinsale) shows Lilly's work is not done -- even if US drug shortages seem to calm down, the expectation of high, ongoing demand remains," said analysts at BMO Capital Markets in a note. This expansion will bolster the facility's capacity to meet the growing demand for medications addressing diabetes and obesity. The Kinsale site employs a digital-first approach and continuous manufacturing technology to produce complex peptides. It also boasts the largest privately owned solar farm in Ireland, which supplies a significant portion of the facility's power. "These investments will boost the production of some of our medicines, helping millions of people with diabetes, obesity and Alzheimer's disease live the healthiest lives possible," said Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations Additionally, Lilly's Global Business Solutions center in Cork has seen growth, with employment levels expected to exceed 2,000 by the end of 2024, underscoring the company's ongoing investment in Ireland.

Lilly expands manufacturing footprint in Ireland with $1.8 billion investment - Eli Lilly (NYSE:LLY)

Company ups manufacturing investment in Limerick by $1 billion; unveils new $800 million Kinsale facility New investment will enhance global medicine production, benefiting millions of patients worldwide INDIANAPOLIS, Sept. 12, 2024 /PRNewswire/ -- Eli Lilly and Company LLY today announced a $1 billion expansion of its Limerick, Ireland, manufacturing site to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. The company also unveiled its new $800 million facility expansion in Kinsale, Ireland, which began making medicines last year to meet demand for Lilly's latest diabetes and obesity treatments. This additional investment is part of the most ambitious manufacturing expansion agenda in the company's history. Since 2020, Lilly has committed more than $20 billion to build, expand and acquire manufacturing facilities in the U.S. and Europe. "These investments will boost the production of some of our medicines, helping millions of people with diabetes, obesity and Alzheimer's disease live the healthiest lives possible," said Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations. "We won't stop there - these state-of-the-art facilities will also be equipped to support our promising pipeline molecules of the future." Limerick, Ireland Once complete, Limerick will join Lilly's global manufacturing network producing the biologic active ingredients for the company's Alzheimer's disease portfolio and other biologic medicines. "Alzheimer's disease is a devastating diagnosis for both the patient and for their loved ones, along with having a huge burden on society," said Anne E. White, executive vice president and president of Lilly Neuroscience. "The treatments we will make here in Limerick offer the potential to be able to slow the progression of the disease and make life better for millions of people around the world." Today's announcement brings Lilly's total Limerick investment to $2 billion, doubling the investment the company announced in March 2023. Advanced technologies such as machine learning, AI and automated robotics and systems at the site will enable right-first-time execution, all in support of the safe and reliable supply of medicines. As a part of this expansion, Lilly will create another 150 jobs for highly skilled workers in Limerick such as engineers, scientists, quality assurance professionals and operations personnel, for a total of 450 employees. Lilly initially announced the Limerick site in 2022 and broke ground in March 2023. Production of biologic active ingredients for Lilly medicines is on track to start in 2026. The Limerick investment project is subject to planning approval, and the company will submit a planning application to the Limerick City and County Council in due course. Kinsale, Ireland Lilly remains dedicated to addressing major global health issues, and the Kinsale facility is pivotal to maintaining the safe and reliable supply of Lilly's diabetes and obesity medications. The official opening of Lilly's Kinsale manufacturing site expansion marks the completion of the state-of-the-art project to help meet the demand for current and future treatments. The site employs a digital-first process that integrates continuous manufacturing technology to create a new manufacturing platform for creating complex peptides. This facility was recently recognized as the winner of the Innovation category in the prestigious "Facility of the Year" awards program run by the International Society of Pharmaceutical Engineers. Ireland's skilled workforce, regulatory environment and pro-innovation government policies have contributed to Lilly's nearly fifty-year presence in the country. In parallel with our manufacturing growth, Lilly's Global Business Solutions center in Cork has quadrupled employment levels since 2019, with more than 2,000 employees expected by the end of 2024, over half of whom are working in clinical research and development. Sustainability Lilly has a long-standing commitment to sustainability and respecting the local environment, establishing environmental programs across all sites in Ireland to monitor the quality of the ambient air, the flora and fauna and the local marine habitat. Once completed, the Limerick site will operate with 35% lower energy intensity, use 40% less water, and generate 15% less waste than traditional biopharmaceutical manufacturing processes. In Kinsale, Lilly has the single largest privately owned solar farm - 26 acres - in the Republic of Ireland, which powers a significant portion of the facility. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn. C-LLY This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about planned capital investments in manufacturing sites and reflects Lilly's current beliefs and expectations. There are substantial risks and uncertainties in the manufacturing process, development, and commercialization of pharmaceutical products which could impact the overall commercial success of our products. For further discussion of risks and uncertainties relevant to Lilly's business that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. Refer to: Carla Cox; [email protected]; +1 317-750-3923 Joe Fletcher; [email protected]; +1 317-296-2884 View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-expands-manufacturing-footprint-in-ireland-with-1-8-billion-investment-302245823.html SOURCE Eli Lilly and Company Market News and Data brought to you by Benzinga APIs